Background: Dilute Russell's viper venom time (dRVVT) is indispensible in lupus anticoagulant (LA) detection yet commercial reagents from different suppliers perform variably, no gold standard assays exist and therapeutic anticoagulation interference is problematic. Objective: The objective of this study was to compare a new formulation dRVVT with two currently available dRVVTs. Materials and methods: Life Diagnostics (LD) dRVVT and Stago PTT-LA were routinely used for lupus anticoagulant detection, plus Taipan snake venom time/ ecarin time (TSVT/ET) for patients on warfarin or rivaroxaban. Siemens dRVVT and the new HYPHEN BioMed (HBM) dRVVT were tested with 193 patient samples. Group 1, 59 nonanticoagulated patients (NAPs) LA-positive in LD dRVVT; Group 2, 15 PTT-LA-positive/ dRVVT-negative NAPs; Group 3, 24 LA-positive warfarinized patients; Group 4, 13 patients on rivaroxaban; Group 5, 62 LA-negative thrombotic NAPs; Group 6, 20 warfarinized, nonantiphospholipid syndrome patients. Results: Accepting that the Life Diagnostics reagents were acting as a pseudo-gold standard, Siemens dRVVT detected 56/59, (95%) Group 1 LA and HBM dRVVT 46/59, (76%), one each from Group 2, and Siemens dRVVT detected one in Group 5. The lower HBM dRVVT detection rate mainly concerned weaker LA, where between-reagent concordance is problematic. All Group 3 patients appeared LA-positive in undiluted plasma with Siemens dRVVT, as did 16/24 (67%) with HBM dRVVT but the fewer LA-positives in mixing tests better mapped to clear LA-positives with LD dRVVT. LD and Siemens dRVVTs exhibited 87% and 95% false-positivity for Group 6 whilst HBM dRVVT had none. Increasing the cut-off improved accuracy. Applying higher cut-offs improved accuracy in Group 4 patients. Conclusion: HBM dRVVT exhibited improved specificity, mainly due to less interference by anticoagulation, but reduced sensitivity, compared to the other dRVVTs employed. Lupus (2018) 27, 95-104.
Introduction
Antiphospholipid syndrome (APS) is diagnosed when laboratory assays demonstrate persistent antiphospholipid antibodies (aPL) in patients with vascular thrombosis or pregnancy morbidity. 1 Since thrombosis and pregnancy morbidity are non-specific for APS, its diagnosis is reliant on accurate and timely aPL detection. Lupus anticoagulant (LA), a criterion aPL, cannot be truly quantified and its presence is inferred based on antibody behaviour in a medley of phospholipiddependent coagulation assays. 2 No single coagulation test is sensitive for all LA and two test systems of differing analytical principles are needed to maximize detection rates. [2] [3] [4] [5] The medley for each test type comprises a screening test to reveal an in vitro, prolonged clotting time, a mixing test to reveal the presence of an inhibitor and a confirmatory test for phospholipid dependence. All current guidelines recommend that dilute Russell's viper venom time (dRVVT) must be one of these tests, [2] [3] [4] [5] mainly due to the reagent's high specificity in detecting clinically significant LA, normally partnered with LA-responsive activated partial thromboplastin time (APTT).
Despite near ubiquity in LA-detection repertoires, differences in diagnostic performance between dRVVT reagents have been described, [6] [7] [8] [9] [10] even between reagents with potentially common manufacturing processes/sources. 2, 8 Another problem with detecting LA by dRVVT is interference from therapeutic anticoagulation. Debate persists about whether reliable analysis is possible on undiluted plasma from patients receiving vitamin K antagonists (VKA), 11, 12 and whilst mixing tests can correct the VKA effect and reveal a LA, the dilution factor can lead to false-negative results.
2-5, 13 Most commercial dRVVT reagents contain heparin neutralizers that permit testing in patients receiving heparins providing quenching capacity is not exceeded, which is most likely to be achieved with low dose subcutaneous unfractionated heparin (UFH) and low molecular weight heparin, rather than high dose therapeutic UFH. 2, 4, 5, 13 Direct oral anticoagulants (DOACs) interfere with dRVVT, often generating false-positive interpretations by inducing greater elevation of screen than confirm results, and also elevating mixing tests. 10, [14] [15] [16] [17] Being one of the first DOACs available, rivaroxaban has received more attention in the literature and the occurrence of falsepositives appears reagent-dependent, with some reagents generating few or no false-positives. 10, 17 A recently available, new formulation dRVVT screen and confirm reagent pair, HEMOCLOT TM LA-S and HEMOCLOT TM LA-C (HYPHEN BioMed, Neuville-sur-Oise, France), are claimed to be less influenced by the low coagulation activity of warfarin and rivaroxaban than other commercial dRVVT reagents. The present study evaluates the diagnostic performance of these reagents against two established dRVVT reagent pairs in detection of LA in a variety of patient cohorts.
Materials and methods

Blood collection, manipulation and storage
Blood was collected into Vacuette
Õ tubes (Greiner Bio-One Ltd, Stonehouse, UK) containing a one tenth volume of 0.105 M (3.2%) tri-sodium citrate and double centrifuged to obtain platelet poor plasma (PPP), [3] [4] [5] which was stored at À80 C until use.
Lupus anticoagulant assays
Routine LA detection employed dRVVT and LAsensitive APTT test medleys, performed and interpreted in accordance with current guideines. 4, 5, [17] [18] [19] on undiluted plasma using Diagen Taipan venom and diluted Diagen Bell and Alton Platelet Substitute (Diagnostic Reagents, Thame, UK). Echis carinatus venom (Diagnostic Reagents) was used for the ecarin time (ET) confirm test. All LA assays were performed on a Sysmex CS2000i analyzer (Sysmex UK, Milton Keynes, UK). Screen and confirm clotting times were converted to normalized ratios via their reference interval (RI) mean clotting times. 5, 8, 11, 20 This approach to ratio generation was adopted to mitigate for systematic bias that can ensue if normal pooled plasma (NPP) clotting times are distant from RI mean clotting times. 5, 13, 20 Results were defined as consistent with the presence of a LA if the screen ratio was greater than the RI upper limit with ! 10% correction by the confirm ratio. [3] [4] [5] [6] 18, [20] [21] [22] Mixing tests with screen and confirm assays were performed for dRVVT and dAPTT to increase specificity, 4, 5 particularly where confirm ratios were themselves elevated.
5, 23 In view of potential differences between NPP and RI mean clotting times, 5, 20 mixing test ratios were derived from NPP results as denominator so that the ratios reflected the effect of index plasmas on the NPP in which they were mixed. Mixing test specific cut-off was employed to determine the presence of inhibition. 3, 5, 21, 24 The RIs, and thus cut-offs, had previously been locally derived from 43 normal donor plasmas. [3] [4] [5] 25 All had Gaussian distributions and were calculated as AE 2 standard deviations (SD) of the mean. 4, 5, 25 Additional dRVVT reagents Siemens LA1 and LA2 (Sysmex UK), and HYPHEN BioMed (HBM) HEMOCLOT TM LA-S and HEMOCLOT TM LA-C were performed on a Sysmex CS2400 analyzer (Sysmex Corporation, Kobe, Japan). Screen, confirm and mixing test results were initially manipulated as described above. Although routine testing employed percentage correction of elevated screen to determine phospholipid dependence, normalized screen ratio/confirm ratio (NSCR) was subsequently applied to more easily present and compare between-reagent data, and is recommended by Siemens and HBM for their reagents. [2] [3] [4] [5] Reference intervals were derived from 50 normal donor plasmas using CRYOcheck TM Normal Donor Sets (Alpha Labs). Intra-assay precision for screen and confirm ratios was assessed from assaying the CRYOcheck TM Normal Reference Plasma and a strong LA-positive plasma 10 times each. Inter-assay precision was assessed with the same plasmas from five consecutive runs.
Controversy exists as to whether cut-offs derived from non-anticoagulated patients should be applied to testing on undiluted plasma from patients anticoagulated with VKA. 2, 3, [11] [12] [13] 18 A report subsequent to current guidelines has suggested that increasing the NSCR cut-off for dRVVT to 1.7 achieved a sensitivity of 81.3% and specificity of 99.1%. 26 Although not locally derived, we additionally applied this cut-off to dRVVT data on warfarinized patients to broadly assess the effect of applying a higher cut-off.
Patients
Samples from 193 patients with LA requests at Guy's and St. Thomas' Hospitals, divided into six sub-groups, were subsequently analyzed with the additional dRVVT reagents. The sub-groups are detailed in Table 1 , which includes international normalized ratio (INR) data for patients on warfarin.
Results
Performance variation between dRVVT reagents is widely reported and can be reduced by converting clotting times to normalized ratios and generating cut-offs specific to given analyzer/reagent pairings. [2] [3] [4] [5] [6] 22, 27 The established RIs for LD reagents and newly generated RIs for Siemens and HBM reagents are shown in Table 2 , the upper limits operating as cut-offs. Data for Siemens and HBM reagents were Gaussian and calculated as AE 2 SD of the mean. 4, 5, 25 Intra-assay and inter-assay precision data for screen and confirm assays of LD, Siemens and HBM reagents are shown in Table 3 .
Non-anticoagulated patients
Between-reagent correlations and Bland-Altman plots for NSCR in patients from Groups 1, 2 and 5 are shown in Figure 1 . Siemens dRVVT detected 56/59 (95%) of the LA in Group 1 and HBM dRVVT detected 46/59 (76%), and they detected one each of the LA from Group 2. The Siemenspositive sample (screen ratio 1.22, 16.7% correction, NSCR, 1.20) was from a patient with transient ischemic attacks, persistently positive for LA by dAPTT. The HBM-positive sample (screen ratio 1.23, 20.2% correction, NSCR, 1.25) was from a patient with Behc¸et disease, persistently positive for LA by dAPTT. Because generating NSCRs to better compare between-reagent data involves simultaneous performance of screen and confirm assays, so-called integrated testing, 2,3,9,11,13 some samples with initially normal dRVVT screen ratios generated elevated NSCRs. Siemens dRVVT generated three elevated NSCRs from samples in Group 5 of 1.14, 1.16 and 1.13, but only the first had an elevated screen ratio, of 1.24, with 12.4% correction, and was likely a weak LA. 2 The HBM dRVVT generated five elevated NSCRs in Group 5 samples, of 1.16, 1.16, 1.19, 1.19 and 1.24, but none had elevated screen ratios and would not have qualified for confirmatory testing. Thus, between-reagent agreement for LA-negative samples in non-anticoagulated patients was good.
Anticoagulated patients
All Group 3 patients were known to have persistent LA prior to receiving warfarin via the routine reagents. Routine testing disregarded dRVVT and dAPTT on undiluted plasma and relied on their screen and confirm mixing studies plus TSVT/ ET. 4, 5, 18 Eleven of 24 were LA-positive in all three assays, 3/24 with dRVVT/TSVT/ET, 3/24 with dAPTT/TSVT/ET, 6/24 with TSVT/ET only and 1/24 with dRVVT only. Accepting that interpreting dRVVTs on undiluted plasma from warfarinized patients is controversial, 2, [11] [12] [13] 18 all Group 3 patients were LA-positive with Siemens dRVVT in undiluted plasma and 17/24 (71%) in mixing studies, and HBM dRVVT 16/24 (67%) in undiluted plasma and 11 of 21 with sufficient plasma for mixing studies (52%). However, all samples LAnegative in Siemens and HBM dRVVT mixing studies were also negative in LD dRVVT mixing studies but positive with TSVT/ET, two of which were also positive in dAPTT mixing studies. Isert et al. proposed a warfarin-specific dRVVT NSCR cut-off for undiluted plasma of 1.70 with their reagent/analyzer pairing. 26 Application of that dRVVT reagent variation GW Moore et al.
cut-off to these data reduced false-positives in the non-APS patients of Group 6 to zero, but reduced frequency of LA-positivity in Group 3 on undiluted plasma with Siemens dRVVT to 12/24 (50%), and 8/24 (33%) for HBM dRVVT. Eleven of those LA-positive with Siemens dRVVT and all with HBM dRVVT were LA-positive in LD dRVVT mixing tests. Although undiluted plasma results with LD dRVVT were not assessed routinely, retrospective evaluation revealed 23/24 (96%) LA-positive results with the standard cutoff and 11/24 (46%) with the higher cut-off. Four of the patients in Group 4 had an established APS diagnosis with persistent LA prior to anticoagulation and the others were anticoagulated for venous thrombosis and receiving initial investigations for aPL. Patterns of LA assay positivity in Group 4 are shown in Table 4 . Locally evaluated rivaroxaban-specific cut-offs for undiluted plasma with LD reagents from known APS patients suggest that > 40% correction or NSCR > 1.60 can increase specificity and results with those cut-offs are shown in Table 5 . The increased cut-offs detected all four known LA and suggested the presence of LA in two of the thrombotic patients, one of whom was dAPTT-positive and the other TSVT/ET positive with a subsequent sample eight months later. The Siemens reagents identified the same six patients as LA-positive when applying those cut-offs and gave concordant interpretations for five of the LA-negative thrombotic patients. The other two had percent corrections of 45.5 and 39.2, NSCRs of 1.84 and 1.64 and were also dAPTT-positive with elevated anti-b2glycoprotein I antibodies. The HBM reagents detected two of the LA in APS patients and one in the thrombotic patients with LD and Siemens NSCRs > 1.60. AntiXa levels were not available on these samples but all had elevated LD confirm ratios (range 1.15-2.70, mean 1.86, median 1.65), which were taken as a surrogate indicator of the presence of rivaroxaban.
Prothrombin times could not be employed for this purpose as a rivaroxaban-insensitive thromboplastin 16 was in routine use. Based on standard cutoffs for undiluted plasma in the known LA-positive patients on warfarin and rivaroxaban, the HBM reagents detected the LA in 18/28 (64.3%).
Discussion
Diagnosis of APS is ultimately reliant on laboratory tests, so diagnostic accuracy of LA assays is crucial. [1] [2] [3] [4] [5] 13, 21 The two other criteria antibodies are anticardiolipin and anti-b2 glycoprotein I antibodies, both of which are detected in solid-phase assays. 1 Clinically appropriate patients with persistence of one or more criteria antibodies can be considered to have APS. 1 Standard interpretation criteria for LA assays necessarily assume a patient's coagulation is otherwise normal, and results in nonanticoagulated patients can often be interpreted at face value.
2,4,5, 23 The patients in Groups 1 and 2 had an established diagnosis of APS and/or systemic lupus erythematosus, all with persistent LA. None were anticoagulated, permitting direct comparison of diagnostic outcomes between reagents. Siemens dRVVT detected 95% of the LA in Group 1 and HBM dRVVT detected 76%. This degree of variation has been reported previously, [6] [7] [8] 24 and it is important to acknowledge that, since the LD reagents were employed for routine diagnostics to detect LA in the first place, they were effectively used as a pseudo-gold standard, unavoidable in LA testing and thus introducing a selection bias, and a different outcome could have ensued if other reagents were employed routinely. The two additional LA detected by Siemens and HBM reagents in Group 2 further reflect this phenomenon, although the majority of Group 2 samples remaining dRVVT-negative is testament to the necessity for an additional assay of different principle to account for antibody heterogeneity. Classically, confirmatory and mixing tests are not initiated unless the screen is elevated, [2] [3] [4] [5] although adoption of the logistically convenient integrated model, whereupon NSCRs are generated on every patient, is becoming increasingly common. 2, 5, 8, 26 Differing outcomes have been reported when applying alternative interpretation models, 7, 23 which was seen in the LA-positivity with Siemens and HBM reagents by NSCR in three and five samples, respectively, from Group 5. Although only one had an elevated screening test to qualify it for reflex testing, a laboratory routinely reporting integrated results would classify them as LA-positive and they may be genuine LA that did not manifest with LD reagents. [6] [7] [8] This could also be due to the phenomenon of weak, or low-titre, LA that either minimally prolong screening test clotting times, 2, 28, 29 or in some cases, prolong clotting times above a patient's baseline but not sufficient to exceed a cut-off. 2, 30 Between reagent correlations for NSCR exhibited better numerical agreement between the LD and Siemens reagents than either with the HBM reagents, likely reflecting similar composition. 2, 8 Bland-Altman plots were expressed as percentages as the correlation plots suggested variability increase as measurement magnitude increased when comparing HBM reagents to the other two. 31 Although most values were within 95% limits of agreement there was a clear positive bias with the HBM reagents as NSCR increased, suggesting results are more clear cut with potent antibodies; yet this was balanced by a reduction in detection of some of the apparently weaker antibodies, accounting for the lower detection rate. The positive bias with HBM reagents at higher NSCRs was largely due to the screen ratios being higher than with the other two reagents; the median screen ratios in Group 1 for LD, Siemens and HBM positives were 1.39, 1.45 and 1.63, respectively. The virtual absence of bias at normal NSCRs explains the good agreement between all three reagents with LA-negative samples from non-anticoagulated patients. Between-reagent and between-laboratory discrepancies for weaker LA are commonly reported by external quality assurance schemes 7, 28, 29 and some workers debate whether they are clinically significant or even genuine LA. 9, 32 All therapeutic anticoagulants have the potential to compromise LA testing with some or most available assays and testing is best postponed until anticoagulant treatment is discontinued. [3] [4] [5] Despite this, it is common for samples from anticoagulated patients to be submitted for diagnostic LA testing. 7, 10 The high rate of false-positivity with LD and Siemens reagents in Group 6 patients emphasizes that dRVVT testing on undiluted plasma from VKA anticoagulated patients can be unreliable. This is an important consideration because integrated testing, without mixing tests, is gaining in popularity. 29, 33 Whilst mixing tests can be useful in correcting the VKA anticoagulant effect and have the potential to reduce the false-positivity encountered when testing undiluted plasma, the dilution effect from mixing tests is a major cause of false-negative LA testing. [2] [3] [4] [5] 13, 18, 28, 29 There was insufficient plasma from the Group 6 patients to perform mixing tests, and in any case, the zero rate of false-positivity with the HBM reagents aligns with the manufacturer's claim of reduced interference by VKAs. This is also borne out by seven of these patients having normal HBM screening test ratios, and the lower mean and median ratios than the other reagents for those that were elevated. An important observation is that, although many of the HBM dRVVT screen ratios were elevated (range 0.96-1.76, median 1.23), all were accompanied by concordant or higher confirm ratios (range 1.13-1.87, median 1.53), thereby generating normal NSCRs. The LD and Siemens reagents appeared to have high detection rates of known LA in undiluted plasma from Group 3 samples, yet the false-positivity with Group 6 samples and reduction in detection rates with the increased cut-off suggests that some may have been partly or wholly due to screen and confirm reagent variables in the presence of the VKA anticoagulant effect. 4, 5, 12, 13, 23, 26 The samples with negative mixing studies with all three dRVVT reagents but positivity with TSVT/ET and/or dAPTT mixing studies were likely manifestations of antibody heterogeneity and the dilution effect. [2] [3] [4] [5] 10, 11, 13, 18, 21, 23, 24 Application of the elevated cut-off eliminated false-positives in non-APS plasmas but reduced sensitivity to known LA. Positivity via the elevated cut-off was mirrored in the majority of mixing studies for those samples with all reagents, suggesting good discrimination with the higher cut-off. Application of a cut-off from a different reagent/analyzer pairing is a limitation to this section of the study, yet it serves to align with the report from Isert et al. that higher cut-offs can improve dRVVT testing in this patient population. 26 Additionally, a number of commercially available dRVVT reagents behave similarly in comparison studies, 8 likely due to common sources, 2 and the analyzer in the present study employs the same end-point detection principle as that of the instrument used by Isert et al. 6, 26 All Group 4 patients were positive with LD and Siemens dRVVTs, suggesting the recognized rivaroxaban-induced screen and confirm discordance exaggeration may have manifested in at least some samples. 10, [14] [15] [16] [17] Applying drug-specific cutoffs generated clear demarcation between known LA and most other patients, and the thrombotic patients with similar percent correction and NSCR values to known LA were considered likely genuine LA in view of their other LA assay results. Similar to warfarinized patients, screen and confirm ratios for HBM dRVVT-negative samples were ostensibly concordant. Applying standard cutoffs detected two of the known LA in APS patients and the likely LA in one of the thrombotic patients. A limitation of the study is the low numbers of samples from patients on rivaroxaban known to have LA. Accruing residual plasmas from such patients is problematic since rivaroxaban is not routinely monitored, but the data showing concordant HBM screen and confirm ratios in apparently LA-negative patients give credence to the claim of reduced interference.
Accurate cut-off generation is crucial to effective LA detection. The International Society on Thrombosis and Haemostasis (ISTH) guideline recommends cut-offs derived from the 99th percentile, which has proven controversial, partly because the 40 normal donor recommendation may not be sufficient for an accurate 99th percentile.
2,4,5,13,25 The British Society for Haematology (BSH) and the Clinical and Laboratory Standards Institute (CLSI) guidelines additionally indicate that the higher cut-offs from this approach to improving specificity come at a statistically inevitable cost of reduced sensitivity, hence their indications that diagnostically valid cut-offs from parametric statistics and smaller donors numbers can be generated if population distributions are Gaussian, or can be made so by data transformation. 2, 4, 5, 25, 34 More recently, lower cut-offs have been shown to allow better detection rates. 35, 36 Consequently, it is standard local practice to follow the BSH and CLSI recommendations for cut-off generation. The ISTH guidelines recommend only dRVVT and APTT for LA detection, yet both assays are compromised to varying extents by therapeutic anticoagulation. Conversely, the BSH and CLSI guidelines do advocate the additional use of TSVT/ET in appropriately anticoagulated patients, 4, 5 and publications subsequent to the guidelines have evidenced utility of these assays in patients receiving rivaroxaban. 17, 19, [37] [38] [39] Employing TSVT/ET in the present study therefore aided confidence in detection or exclusion of LA in these patients.
Intra-assay and inter-assay precision were slightly higher with the HBM screening reagent compared to the others but all were below 2.5% and acceptable for routine diagnostic use.
Although many currently available commercial dRVVT reagents behave similarly in diagnostic comparisons, deviations do occur that may be more noticeable in a given reagent. 6, [8] [9] [10] The LD and Siemens reagents exhibited close diagnostic agreement in all patient groups. The performance of the HBM reagents exhibited good diagnostic concordance for LA-negative samples but reduced sensitivity compared to those specific reagents yet clearly less interference by warfarin and rivaroxaban, where poor specificity is a common problem. Two other commercially available dRVVT reagents have exhibited similar LA detection rates in comparison with other dRVVT reagents to that exhibited by HBM reagents in this study. 6, [8] [9] [10] One is another new reagent exhibiting reduced anticoagulant interference, 10 and the other in more regular use, 29 which has been employed in reference laboratories. 40 Chantarangkul et al. concluded from their study that recommended analytical criteria cannot be generalized to all LA assays, even same-principle reagents, and practitioners should tailor their approach based on local experience with a given reagent and appropriate clinical consideration regarding sensitivity versus specificity. 9 Mixing tests can improve specificity 2,4,5,9 yet the increasing adoption of integrated testing without mixing tests may reduce diagnostic effectiveness, 9, 18, 21, 23 and new formulation dRVVT reagents with improved specificity 10 may have a role in laboratories adopting this approach. Where suspension of oral anticoagulation or brief replacement with low molecular weight heparin cannot be considered, an optimal LA detection approach could comprise sensitive dRVVT AE drug-specific cut-off, more specific new formulation dRVVT, dAPTT and TSVT/ET.
